|本期目录/Table of Contents|

[1]徐志强,张 敏.儿童门静脉高压症研究进展[J].传染病信息,2019,05:456-461.
 XU Zhi-qiang,ZHANG Min*.Research progress of portal hypertension in children[J].Infectious Disease Information,2019,05:456-461.
点击复制

儿童门静脉高压症研究进展(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2019年05期
页码:
456-461
栏目:
综述
出版日期:
2019-11-13

文章信息/Info

Title:
Research progress of portal hypertension in children
文章编号:
1007-8134(2019)05-0456-06
作者:
徐志强张 敏
 100039 北京,中国人民解放军总医院第五医学中心青少年肝病诊疗与研究中心(徐志强、张敏)
Author(s):
XU Zhi-qiang ZHANG Min*
Pediatric Liver Diseases Treatment and Research Center, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
关键词:
儿童门静脉高压症病因诊断治疗
Keywords:
children portal hypertension etiology diagnosis treatment
分类号:
R544.1
DOI:
10.3969/j.issn.1007-8134.2019.05.019
文献标识码:
A
摘要:
儿童门静脉高压症是指在多种病因作用下,门静脉系统的血流受阻和(或)血流量增加、血管舒缩功能障碍,引起门静脉及其属支的压力持续增高,门静脉压力> 5 mmHg(1 mmHg=0.133 kPa),或门静脉、肝静脉压力梯度> 10 mmHg,最终导致脾大、门腔侧支循环形成和开放、腹水等临床表现,是一种血流动力学异常综合征。儿童门静脉高压症根据病因不同分为肝硬化性门静脉高压症和非肝硬化性门静脉高压症;根据压力来源的解剖部位,可将门静脉高压症分为肝前性、肝内性(窦前性、窦性、窦后性)及肝后性。治疗方法有药物治疗、曲张静脉套扎或硬化、手术治疗等。虽然儿童门静脉高压症发病率较低,但可以引起胃食管静脉曲张破裂出血、肝性脑病等严重并发症。为加强对本病的认识,减少并发症,提高治愈率,现将其病因分类、发病机制、诊断和治疗方面的研究进展作一综述。
Abstract:
Portal hypertension in children refers to the blocked and/or increased blood flow of the portal vein system and thedysfunction of vasodilation and contraction caused by various causes, resulting in continuous increase of pressure of the portal veinand its branches. The pressure of the portal vein exceeds 5 mmHg (1 mmHg=0.133 kPa), or the pressure gradient of the portal veinand hepatic vein exceeds 10 mmHg, eventually leading to the formation and opening of the splenomegaly and portacaval collateralcirculation, as well as ascites and other clinical manifestations. It is an abnormal hemodynamic syndrome. Portal hypertension in children can be divided into cirrhotic portal hypertension and non-cirrhotic portal hypertension according to the etiology. According to theanatomical location of pressure source, portal hypertension can be divided into pre-hepatic, intrahepatic (pre-sinusoidal, sinusoidal,post-sinusoidal) and post-hepatic. Therapeutic methods include drug therapy, varicose vein ligation or sclerosis, surgical treatment,etc. Although the incidence of portal hypertension in children is low, it can cause severe complications such as gastroesophagealvarices bleeding and hepatic encephalopathy. In order to strengthen the understanding of this disease, improve the cure rate and reduce complications, this paper reviews the progress in etiological classification, pathogenesis, diagnosis and treatment of the disease.

参考文献/References

[1] Mileti E, Rosenthal P. Management of portal hypertension in children[J]. Curr Gastroenterol Rep, 2011, 13(1):10-16.
[2] McKiernan P, Abdel-Hady M. Advances in the management of childhood portal hypertension[J]. Expert Rev Gastroenterol Hepatol, 2015, 9(5):575-583.
[3] Procopet B, Tantau M, Bureau C. Are there any alternative methods to hepatic venous pressure gradient in portal hypertension assessment?[J]. J Gastrointestin Liver Dis, 2013, 22(1):73-78.
[4] Ebel NH, Carlin K, Shaffer ML, et al. Hepatic venous pressure gradient measurements in children: correlation with hepatic histology and clinical indicators of portal hypertension[J]. J Pediatr Gastroenterol Nutr, 2019, 68(6):788-792.
[5] de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3):743-752.
[6] European Association for the Study of the Liver.EASL clinicai practice guidelines: vascular diseases of the liver[J]. J Hepatol, 2016, 64(1):179-202.
[7] Martín-Llahí M, Albillos A, Ba?ares R, et al. Vascular diseases of the liver. Clinical guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver [J]. Gastroenterol Hepatol, 2017, 40(8):538-580.
[8] Gracia-Sancho J, Maeso-Díaz R, Fernández-Iglesias A, et al. New cellular and molecular targets for the treatment of portal hypertension[J]. Hepatol Int, 2015, 9(2):183-191.
[9] 赵连晖,贾继东. 应重视门静脉高压症的病因诊断及规范治 疗[J]. 临床肝胆病杂志,2019,35(1):10-12.
[10] Sahin A, Artas H, Tunc N, et al. Hematological indices in portal hypertension: cirrhosis versus noncirrhotic portal hypertension[J]. J CIin Med, 2018, 7(8):pii:e196.
[11] Tseng Y, Ma L, Luo T, et al. Non-invasive predictive model for hepatic venous pressure gradient based on a 3-dimensional computed tomography volume rendering technology[J]. Exp Ther Med, 2018, 15(4):3329-3335.
[12] 林姗姗,刘燕娜,祁小龙.门静脉高压症的无创检查[J]. 临床肝胆病杂志,2019,35(1):33-37.
[13] Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2017, 65(1):310-335.
[14] Berzigotti A, Seijo S, Arena U, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis[J]. Gastroenterology, 2013, 144(1):102- 111.
[15] You MW, Kim KW, Pyo J, et al. A meta-analysis for the diagnostic performance of transient elastography for clinically significant portal hypertension[J]. Ultrasound Med Biol, 2017, 43(1):59- 68.
[16] Berzigotti A. Non-invasive evaluation of portal hypertension using ultrasound elastography[J]. J Hepatol, 2017, 67(2):399-411.
[17] Attia D, Schoenemeier B, Rodt T, et al. Evaluation of liver and spleen stiffness with acoustic radiation force impulse quantification elastography for diagnosing clinically significant portal hypertension [J]. Ultraschall Med, 2015, 36(6):603-610.
[18] Gioia S, Nardelli S, Pasquale C, et al. NaturaI history of patients with non cirrhotic portal hypertension: comparison with patients with compensated cirrhosis[J]. Dig Liver Dis, 2018, 50(8):839- 844.
[19] Rawat D, Kelly DA, Milford DV, et al. Phenotypic variation and long-term outcome in children with congenital hepatic fibrosis[J]. J Pediatr Gastroenterol Nutr, 2013, 57(2):161-166.
[20] Wehrmn A, Kriegermeier A, Wen J. Diagnosis and management of hepatobiliary complications in autosomal recessive polycystic kidney disease[J]. Front Pediatr, 2017, 5:124.
[21] 胆汁淤积性肝病诊断治疗专家共识2015 年更新专家委员会. 胆汁淤积性肝病诊断治疗专家共识:2015 年更新[J]. 临床 肝胆病杂志,2015,13(10):1563-1574.
[22] Siramolpivvat S, Seijo S, Miquel R, et al. Idiopathic portal hypertension: natural history and long-term outcome[J]. Hepatology, 2014, 59(6):2276-2285.
[23] European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver[J]. J Hepatol, 2016, 64(1):179-202.
[24] Maurice JB, Brodkin E, Arnold F, et al. Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices[J]. J Hepatol, 2016, 65(5):899-905.
[25] 徐航飞,丁惠国. 肝(窦)前型非肝硬化门静脉高压症的诊 断与治疗及其面临的困境[J]. 临床肝胆病杂志,2019, 35(1):13-17.
[26] Khanna R, Sarin SK. Idiopathic portal hypertension and extrahepatic portal venous obstruction[J]. Hepatol Int, 2018, 12(Suppl 1):S148-S167.
[27] Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2, 500 autopsies and a new classification of benign hepatocellular nodules [J]. Hepatology, 1990, 11(5):787-797.
[28] Kondo F, Koshima Y, Ebara M. Nodular lesions associated with abnormal liver circulation[J]. Intervirology, 2004, 47(3-5):277- 287.
[29] Moran CA, Mullick FG, Ishak KG. Nodular regenerative hyperplasia of the liver in children[J]. Am J Surg Pathol, 1991, 15(5):449-454.
[30] Citak EC, Karadeniz C, Oguz A, et al. Nodular regenerative hyperplasia and focal nodular hyperplasia of the liver mimicking hepatic metastasis in children with solid tumors and a review of literature[J]. Pediatr Hematol Oncol, 2007, 24(4):281-289.
[31] 刘金晶,李梦涛,李菁,等. 肝结节性再生性增生22 例并 文献复习[J/CD]. 中华临床医师杂志: 电子版,2011, 5(24):7377-7381.
[32] Adar T, Ilan Y, Elstein D, et al. Liver involvement in Gaucher disease - review and clinical approach[J]. Blood Cells Mol Dis, 2018, 68:66-73.
[33] Regenboog M, van Dussen L, Verheij J, et al. Hepatocellular carcinoma in Gaucher disease: an international case series[J]. J Inherit Metab Dis, 2018, 41(5):819-827.
[34] 刘贞利,范作鹏,勾钰淞,等. 不同类型肝窦阻塞综合征的 临床特征、发病机制与诊治[J]. 临床肝胆病杂志,2019, 35(1):208-212.
[35] 中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关 肝窦阻塞综合征诊断和治疗专家共识意见(2017年,南京)[J]. 临床肝胆病杂志,2017,33(9):1627-1637.
[36] Working Subgroup for Clinical Practice Guideline for Aberrant Portal Hemodynamics. Diagnosis and treatment guidelines for aberrant portal hemodynamics: the Aberrant Portal Hemodynamics Study Group supported by the Ministry of Health. Labor and Welfare of Japan[J]. Hepatol Res, 2017, 47(5):373-386.
[37] Martens P, Nevens F. Budd-Chiari syndrome[J]. United Eur Gastroenterol J, 2015, 3(6):489-500.
[38] 中华医学会放射学分会介入学组. 布加综合征介入诊疗规范 的专家共识[J]. 中华放射学杂志,2010,44(4):345-349.
[39] Grus T, Lambert L, Grusová G, et al. Budd-Chiari syndrome[J]. Prague Med Rep, 2017, 118(2-3):69-80.

备注/Memo

备注/Memo:
[基金项目]首都临床特色应用研究课题(Z161100000516176)
[作者单位]100039北京,中国人民解放军总医院第五医学中心青少年肝病诊疗与研究中心(徐志强、张敏)
[通信作者]张敏,E-mail:gcmw2001@163.com
*Correspondingauthor,E-mail:gcmw2001@163.com
更新日期/Last Update: 2019-11-13